Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Bisphosphonates for the Treatment of Restenosis

Hila Epstein, Eyal Afergan, Nickolay Koroukhov, Galit Eisenberg, Dikla Gutman, and Gershon Golomb [Pg.187]

Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel [Pg.187]

Other agents such as actinomycin D, C-Myc antisense, dexamethasone, and matrix metalloproteinase inhibitors, aimed at altering inflammatory and smooth muscle actions in the biological repair response to vascular injury, are being evaluated. The success of these devices depends upon multiple issues, including stent platform, carrier, drug properties, and pharmacokinetic profile (18-26). Large randomized, controlled trials, demonstrate a restenosis rate of 5% to 10% with DES (27). [Pg.188]

See other pages where Bisphosphonates for the Treatment of Restenosis is mentioned: [Pg.187]    [Pg.189]    [Pg.191]    [Pg.193]    [Pg.195]    [Pg.197]    [Pg.199]    [Pg.201]    [Pg.203]    [Pg.205]    [Pg.187]    [Pg.189]    [Pg.191]    [Pg.193]    [Pg.195]    [Pg.197]    [Pg.199]    [Pg.201]    [Pg.203]    [Pg.205]   


SEARCH



Bisphosphonate

Bisphosphonates

Restenosis

The Treatments

© 2024 chempedia.info